IgPro20: Clinical Trials

2 trials of IgPro20, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Recruiting 1

Follow IgPro20: new trials by email Literature Review of IgPro20 trials Research Report on IgPro20

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
IgPro20 - Multiple Myeloma, Hypogammaglobulinemia
Phase 2RecruitingMemorial Sloan Kettering Cancer Center1002025-05-082026-10-05
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
IgPro20, IgPro10 - Diffuse Cutaneous Systemic Sclerosis
Phase 2CompletedCSL Behring272019-09-192024-02-05

Conditions studied

Agammaglobulinemia (1)  ·  Common Variable Immunodeficiency (1)  ·  Multiple Myeloma (1)  ·  Scleroderma, Diffuse (1)

Sponsors

CSL Behring (1)  ·  Memorial Sloan Kettering Cancer Center (1)

Countries

Australia (1)  ·  Germany (1)  ·  Italy (1)  ·  Poland (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Zainab Shahid, MBBS (1)

Results publications

PMID 39909490

NIH funding

2018 (1)